Meta-analysis of efficacy and adverse effects of different combination schemes of PD-1/PD-L1 inhibitors in the treatment of ovarian cancer
Objective To investigate the efficacy and side effects of different combined strategies of programmed cell death protein 1(PD-1)/programmed cell death protein 1 ligand(PD-L1)inhibitors in the treatment of advanced ovarian cancer.Methods By searching Pubmed,Embase and Cochrane library,literature on PD-1/PD-L1 immunosuppressants combined with different strategies for ovarian cancer up to November 2023 was collected for quality assessment and data extraction.The meta-analysis was performed using Revman 5.3 and Stata 15.0 software.Results Eleven single-arm studies were included.The results of meta-analysis showed that PD-1/PD-L1 inhibitors combined with different regimens[chemotherapy agents,polyadenosine diphosphoribose polymerase(PARP)inhibitors,and anti-vascular targeting agents]in the treatment of advanced ovarian cancer were clinically beneficial,with an objective response rate of 24％.The heterogeneity was 60％,and the causes were analyzed by subgroups.The results showed that the objective remission rate of PD-1/PD-L1 inhibitor combined with anti-vascular targeted drugs in the treatment of advanced ovarian cancer was 25％,and the disease control rate was 60％.The objective response rate of combined anti-vascular targeting drugs was 64％.Treatment with PD-1/PD-L1 inhibitors combined with different drugs had a progression-free survival rate of 43％at 6 months,26％at 12 months,and 79％overall at 12 months.The incidence of grade 3～5 adverse reactions was 28％,with hypertension,nausea and anemia being the most common.Conclusions PD-1/PD-L1 inhibitors combined with different regiments in the treatment of advanced ovarian cancer significantly improved the survival and prognosis of patients.And the incidence of adverse reactions is considerable.
ovarian cancer bevacizumabPARP inhibitorsimmune checkpoint inhibitorsefficacy safetymeta-analysis
NETL
NSTL
万方数据
